✦ LIBER ✦

An exploratory study of frequent pain measurement in a cancer clinical trial

✍ Scribed by J. Ingham; A. Seidman; T. -J. Yao; J. Lepore; R. Portenoy

Publisher: Springer Netherlands
Year: 1996
Tongue: English
Weight: 573 KB
Volume: 5
Category: Article
ISSN: 0962-9343
DOI: 10.1007/bf00540023

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Controlled-release morphine tablets in p

Controlled-release morphine tablets in patients with chronic cancer pain : A narrative review of controlled clinical trials

✍ Carol A. Warfield 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 143 KB 👁 2 views

## Background: Controlled-release (cr) morphine tablets have become routine therapy in the management of cancer pain. compared with immediate-release (ir) morphine, this formulation provides the benefit of dosing every 12 hours. ## Methods: This study reviewed the 10 published, well controlled, r

Endpoints in cancer clinical trials: is

Endpoints in cancer clinical trials: is there a need for measuring quality of life?

✍ Ronald Feld 📂 Article 📅 1995 🏛 Springer-Verlag 🌐 English ⚖ 456 KB

A distance measure of racial attitudes i

A distance measure of racial attitudes in primary grade children: An exploratory study

✍ Sandra Cohen Koslin; Marianne Amarel; Nancy Ames 📂 Article 📅 1969 🏛 John Wiley and Sons 🌐 English ⚖ 283 KB

SUMMARY MEASURES AND STATISTICS FOR COMP

SUMMARY MEASURES AND STATISTICS FOR COMPARISON OF QUALITY OF LIFE IN A CLINICAL TRIAL OF CANCER THERAPY

✍ DIANE L. FAIRCLOUGH 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 457 KB 👁 3 views

Assessment of health related quality of life (QOL) has become an important endpoint in many clinical trials of cancer therapy. Most of these studies entail multiple QOL scales that are assessed repeatedly over time. As a result, the problem of multiple comparisons is a primary analytic challenge wit

Phase II study of flutamide in patients

Phase II study of flutamide in patients with metastatic breast cancer. A National Cancer Institute of Canada Clinical Trials Group study

✍ Daniele J. Perrault; Diane M. Logan; David J. Stewart; Vivien H. C. Bramwell; Al 📂 Article 📅 1988 🏛 Springer US 🌐 English ⚖ 271 KB

The National Cancer Institute of Canada (NCIC) Clinical Trials Group conducted a phase II study of the oral antiandrogen flutamide in 33 patients with metastatic breast cancer. Eight patients had received no prior systemic therapy for their metastatic disease and 13 had only one site of metastasis.

Phase II study of trimetrexate in malign

Phase II study of trimetrexate in malignant melanoma: A National Cancer Institute of Canada Clinical Trials Group Study

✍ Neill A. Iscoe; Elizabeth A. Eisenhauer; Audley J. Bodurtha 📂 Article 📅 1990 🏛 Springer US 🌐 English ⚖ 183 KB

The National Cancer Institute of Canada Clinical Trials Group carried out a phase II trial of trimetrexate given in a daily x 5 intravenous bolus schedule every 3 weeks in patients with measurable metastatic malignant melanoma who had not received previous chemotherapy. Significant hematologic toxic